Table 1 SNHG6 is an oncogene in tumorigenesis and tumor progression
From: Long noncoding RNA SNHG6 mainly functions as a competing endogenous RNA in human tumors
Cancer type | Function | Cell lines | Assay methods | Isoforms | Molecular mechanism | Reference | Journal |
|---|---|---|---|---|---|---|---|
Gastric cancer | Oncogene | MGC-803,AGS,SGC-7901,BGC-823 | MTT, colony formation, Cell apoptosis and cell cycle analysis, Migration assay | NA | Downregulating the expression of P27 by recruiting EZH2,and function as a competing endogenous RNA for miR-101-3p | Yan et al. [29] | Cell Physiol Biochem |
Breast cancer | Oncogene | BT-474,MDA-MB-231,IR-75-30,T-47-D,MDA-MB-468 | CCK8,EdU,Transwell,Tumorigenicity in nude mice | NA | Functioning as a competing endogenous RNA for miR-26a-5p | lv et al. [39] | Biomed Pharmacother |
Glioma | Oncogene | T98G,U87,U251,LN-229 | CCK8,Cell apoptosis analysis, Invasion assay, Transplanted tumor in nude mice | NA | Functioning as a competing endogenous RNA for miR-101-3p | Meng et al. [43] | Int J Biol Markers |
Osteocarcinoma | Oncogene | KHOS,MG-83,U2OS | MTT, EdU, Colony formation, Cell apoptosis and cell cycle analysis | NA | Downregulating the expression of P21 and KLF2 | Ruan et al. [45] | Arch Biochem Biophys |
Osteocarcinoma | Oncogene | SOSP-9607, MG63 | MTT, colony formation, wound healing and transwell assay, cell cycle and apoptosis ananlysis | NA | Functioning as a competing endogenous RNA for miR-26a-5p | Zhu et al. [49] | Cancer Cell Int |
Colorectal cancer | Oncogene | Lovo,RKO,Ls174t,DLD1,HCT116 | CCK8, Colony formation, Wound healing, Transwell assay, Xenograft model and liver metastasis model | NA | Functioning as a competing endogenous RNA for miR-760 | Zhu et al. [23] | Onco Targets Ther |
Gastric cancer | Oncogene | MGC-803,AGS,SGC-7901,BGC-823,MKN45 | CCK8, Colony formation, Xenograft model in nude mice | NA | Upregulating P21 by decreasing EZH2 and activating JNK | Li et al. [30] | Life sci |
Esophageal squamous cell carcinoma | Oncogene | ECA-109,TE-1 | MTT, Colony formation, Cell apoptosis analysis | NA | NA | Fan et al. [31] | Oncol lett |
Hepatocellular carcinoma | Oncogene | MHCC-77H,HCC-LM3, Huh7, SMMC-7721, BEL-7402 | CCK8, EdU, In vivo tumor growth assay | SNHG6-003 | Functioning as a competing endogenous RNA for miR-26a/b | Cao et al. [18] | Oncogene |
Lung adenocarcinoma | Oncogene | A549,H1299,HCC827,NCI-H358,NCI-H400,NCI-H1650 | MTT, Migration and invasion assay, Wound healing, Xenograft model | NA | Functioning as a competing endogenous RNA for miR-26a-5p | Liang et al. [37] | Biomed Pharmacother |
Colorectal cancer | Oncogene | HCT116, SW480, RKO, Caco-2, SW620, HCT8, Lovo, HT-29 | CCK8, Colony formation, BrdU, Xenograft tumor formation | NA | Repressing P21 transcription through recruiting EZH2 to the P21 promoter | Li et al. [30] | Cell Physiol Biochem |
Colon cancer | Oncogene | HCT-116, Lovo | CCK8, Colony formation, Cell apoptosis analysis | NA | NA | Li et al. [30] | Pathol Res Pract |
Bladder cancer | Oncogene | RT-4, EJ, BIU-87 | Scratch assay, Migration and invasion assay. | NA | Functioning as a competing endogenous RNA for miR-125b and trigger EMT | Journal of Cellular Biochemistry | |
Glioma | Oncogene | U87,SHG44, U251, U373-MG | MTT, Colony formation, Cell apoptosis and cell cycle analysis | NA | Repressing p21 | Cai et al. [44] | Biomed Pharmacother |
Hepatocellular carcinoma | Oncogene | Huh7,HepG2,Hep3B,MHCC97L,HCCLM9, QGY-7701 | CCK8, EdU, Transwell assay, Wound healing, Cell apoptosis analysis, Xenograft model | NA | Functioning as a competing endogenous RNA for miR-101-3p and directly binding UPF1 to activate TGFβ/SMAD pathway | Chang et al. [9] | Cancer Letter |
Hepatocellular carcinoma | Oncogene | Huh7, HCC-LM3, SK-Hep-1, Hep3B | Ultra-performance liquid chromatography | NA | Functioning as a competitive endogenous RNA for miR-1297 and thereby simultaneously activating 2 positive feedback loops to upregulate MAT2A expression and suppress MAT1A expression | Guo et al. [20] | Cancer Res |
Colorectal cancer | Oncogene | HT29, CaCO2, SW480, SW620, RKO, HCT116 and LoVo | CCK8, Transwell assay, Wound healing, Cell apoptosis analysis, In vivo experiments | NA | Activating the TGF-β/Smad pathway via binding UPF1,and functioning as a competing endogenous RNA for miR-101-3p | Wang et al. [10] | Int. J. Med. Sci. |
Colorectal cancer | Oncogene | HCT-116, HCT-8, SW-480, SW-620, DLD-1, and HT-29 | CCK8, Colony formation, EdU, Transwell assay, Wound healing, Cell apoptosis and Cell cycle analysis, Xenograft model | NA | Functioning as a competing endogenous RNA for miR-214-3p, miR-26a-5p, or miR-26b-5p | Xu et al. [24] | Journal of Hematology & Oncology |
Colorectal cancer | Oncogene | HT29, CaCO2, SW480, SW620, HCT116 | MTT, Colony formation, Transwell assay, Wound healing, Cell apoptosis and Cell cycle, Xenograft model | NA | Functioning as a competing endogenous RNA for miR-181a-5p | Yu et al. [25] | Cancer Management and Research |
Colorectal cancer | Oncogene | HT29, RKO, HCT116 | CCK8, Cell apoptosis, Xenograft model | NA | Functioning as a competing endogenous RNA for miR-26a-5p | Wang et al. [10] | Cancer Cell Inter |
Colorectal cancer | Tumor suppressor | NCM460, SW480, HCT116 | MTT, Transwell assay, Wound healing, Cell apoptosis. | NA | Targeting ETS1 via activating PI3K/AKT/mTOR pathway | Meng et al. [43] | Mol Med Rep |
Colorectal cancer | Oncogene | HT29, SW620, HIECs | MTT, Colony formation, Transwell assay. | NA | Functioning as a competing endogenous RNA for miR-101-3p | Shao et al. [12] | BMC gastroenterology |
Hepatocellular carcinoma | Oncogene | HL-7702, HepG2, Hep3b, HLE and Huh-7 | Cell viability assay, Colony formation, Transwell assay, Cell cycle, Xenograft model | NA | Functioning as a competing endogenous RNA for miR-139-5p | Wu et al. [17] | Cell cycle |
Hepatocellular carcinoma | Oncogene | MHCC-97H and HCC-LM3 | CCK8 assay. | NA | Functioning as a competing endogenous RNA for let-7c-5p | Chen et al. [19] | Biochem Biophys Res Commun |
Esophageal squamous cell carcinoma | Oncogene | EC109, EC9706, KYSE30, and KYSE150 | CCK8, Colony formation, Transwell assay. | NA | Functioning as a competing endogenous RNA for miR-186-5p | Du et al. [33] | Dig Dis Sci |
Esophageal squamous cell carcinoma | Oncogene | EC9706, EC109, EC1, HET-1A | Cell proliferation, migration and invasion assays | NA | NA | Zhang et al. [16] | Am J Transl Res |
Breast cancer | Oncogene | EFM192A, AU565, UACC893, MDA-MB- 415, HS742 T, MDA-MB-231, MCF-7 | CCK-8, colon formation, EdU assays, Wound healing, Transwell assay, Cell cycle. | NA | Functioning as a competing endogenous RNA for miR-26a | Li et al. [40] | Pathol Res Pract |
Non-Small Cell Lung Cancer | Oncogene | A549, H226, H292, ANP973 and H1299 | CCK8, Cell apoptosis and Cell cycle, Wound healing, Transwell assay. | NA | Functioning as a competing endogenous RNA for miR-944 and miR-181d-5p | Geng et al. [34] | Onco targets ther |
Non-Small Cell Lung Cancer | Oncogene | A549, H460, and H1299 | MTT, Cell apoptosis, Xenograft model. | NA | Functioning as a competing endogenous RNA for miR-490-3p | Dong et al. [35] | Cancer biother radiopharm |
Non-Small Cell Lung Cancer | Oncogene | A549, NCI-H23, NCI-H1993, NCI-H522 and NCI-H460 | MTT, Transwell assay,Xenograft model | NA | Functioning as a competing endogenous RNA for miR-101-3p | Li et al. [36] | Thorac cancer |